Search Results | Blood | American Society of Hematology

1-20 of 53

2 3

Sort by

Sort Order Select

Journal Articles

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

John Mascarenhas, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Regina Garcia-Delgado, MD, Andrzej Pluta, MD, Hope Qamoos, CNP, Anne Uyei, MD, Damaj Gandhi Laurent, MD PhD, Haifa K Al-Ali

Blood (2020) 136 (Supplement 1): 44–45.

DOI: https://doi.org/10.1182/blood-2020-134262

Published: 2020

Journal Articles

Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-141535

Published: 2020

Journal Articles

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

Blood (2020) 136 (Supplement 1): 47–48.

DOI: https://doi.org/10.1182/blood-2020-137265

Published: 2020

Journal Articles

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Blood (2020) 136 (Supplement 1): 37–38.

DOI: https://doi.org/10.1182/blood-2020-138752

Published: 2020

Journal Articles

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Charlotte K Brierley, MRCP, MD, Alba Rodriguez-Meira, PhD, Matthew Bashton, PhD, Angela Hamblin, MD PhD, Rachel S Fletcher, PhD, Sonia Fox, Charlotte Gaskell, BSc, MSc, Aimee Jackson, BSc, MSc, Jennifer O'Sullivan, MD, Lauren C Murphy, Nikolaos Sousos, MDMSc, Amir Enshaei, PhD, Claire Harrison, DM, FRCP, FRCPath, Mark W. Drummond, PhD FRCPath, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Bethan Psaila, MD PhD, Adam J. Mead, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

DOI: https://doi.org/10.1182/blood-2020-139520

Published: 2020

Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD

Blood (2020) 136 (Supplement 1): 33–35.

DOI: https://doi.org/10.1182/blood-2020-134764

Published: 2020

Journal Articles

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Mark W. Drummond, PhD FRCPath, Charlotte Gaskell, BSc, MSc, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Christina Yap, PhD CStat, Aimee E Jackson, BSc, MSc, Jennifer Byrne, FRCP, FRCPath, PhD, Fiona J Clark, FRCP, FRCPath, Srinivasan Narayanan, FRCP, FRCPath, David Bowen, MD, Tim C.P Somervaille, PhD FRCP, FRCPath, Emma Gudgin, MBBS, MRCP, FRCPath, PhD, Dragana Milojkovic, Rachel S Fletcher, PhD, Charlotte K Brierley, MRCP, MD, Steve Knapper, BMBCh, MRCP, FRCPath, DM

Blood (2020) 136 (Supplement 1): 2–3.

DOI: https://doi.org/10.1182/blood-2020-138437

Published: 2020

Journal Articles

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead

Blood (2019) 134 (23): 2107–2111.

DOI: https://doi.org/10.1182/blood.2019001861

Published: 2019

Includes: Supplemental data

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

DOI: https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Blood (2019) 134 (Supplement_1): 557.

DOI: https://doi.org/10.1182/blood-2019-122546

Published: 2019

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

DOI: https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

DOI: https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

Unravelling Heterogeneity of Stem and Progenitor Cells in Myeloid Neoplasms Through Single Cell Multi-omics

Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): SCI-31.

DOI: https://doi.org/10.1182/blood-2019-121049

Published: 2019

Journal Articles

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Jenny Byrne, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Adam J. Mead, MD PhD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Gavin Campbell, FRCP,FRCPath, Ian Amott, Andrew Goringe, Earnest Heartin, Evangelia Dimitriadou, MD, Ian Pamphlett, Siamak Arami, MD MRCP, FRCPath, Pratap Neelakantan, Rebecca Frewin, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Hugues De Lavallade, Nicholas C.P. Cross, Michael Thompson

Blood (2019) 134 (Supplement_1): 3434.

DOI: https://doi.org/10.1182/blood-2019-122893

Published: 2019

Journal Articles

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Adam J. Mead, MD PhD, Tim Somervaille, Professor, MD, Nauman M Butt, MD, Waseem Nagi, MD FRCPath, Alastair J Whiteway, MBBS, Suriya Kirkpatrick, MD, Ciro R Rinaldi, MD PhD, Catherine Roughley, MD, Sam Ackroyd, MD, Joanne Ewing, PhDBMBS BSc FRPATH, Pratap Neelakantan, MD FRCPath, Mamta Garg, MD FRCP, FRCPath, Claire N Harrison, Professor, David Tucker, MD, Rozinder Bains, Gavin Chiu, MBBS, MRCGP, MFPM, DPM, BSc, Joe Hickey, PhD

Blood (2019) 134 (Supplement_1): 1671.

DOI: https://doi.org/10.1182/blood-2019-124686

Published: 2019

Journal Articles

Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs

Blood (2019) 134 (13): 1059–1071.

DOI: https://doi.org/10.1182/blood.2019001289

Published: 2019

Includes: Supplemental data

Journal Articles

Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation

Bethan Psaila, Adam J. Mead

Blood (2019) 133 (13): 1427–1435.

DOI: https://doi.org/10.1182/blood-2018-11-835371

Published: 2019

Journal Articles

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Jennifer O'Sullivan, MB BCh BAO, Angela Hamblin, MD PhD, Anesh Panchal, BSc, MSc, Christina Yap, MSci, PhD CStat, Sonia Fox, BSc, Samah Alimam, DHSC, MD, Helene Marie-Pierre Dreau, Kieran Howard, Pauline Ware, Samantha Baker, Nicholas C.P. Cross, Mary Frances McMullin, MD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD

Blood (2018) 132 (Supplement 1): 1784.

DOI: https://doi.org/10.1182/blood-2018-99-118220

Published: 2018

Journal Articles

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Ruben A. Mesa, MD FACP, Francisco Cervantes, MD PhD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Lixia Wang, PhD, Tanya Granston, PhD, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 4281.

DOI: https://doi.org/10.1182/blood-2018-99-114779

Published: 2018

Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 690.

DOI: https://doi.org/10.1182/blood-2018-99-110388

Published: 2018

2 3

NARROW

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Unravelling Heterogeneity of Stem and Progenitor Cells in Myeloid Neoplasms Through Single Cell Multi-omics

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs

Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only